Acino will be manufacturing the product at its site in Miesbach, Germany, and will supply the product from there.
Acino Group CEO Peter Burema said the alliance between Sawai and Acino will enhance both
companies’ mid-term growth opportunities.
Acino develops and manufactures generic pharmaceuticals like oral dosage forms with modified release of the active ingredient, transdermal therapeutic patches and biodegradable, subcutaneous implants, using advanced drug delivery technologies.
Acino also offers services from product development and registration to sourcing, contract
manufacturing, packaging and logistics.